A Phase 2 interventional study of FWY003 and Placebo in Geographic Atrophy Secondary to Age-related Macular Degeneration, sponsored by Novartis Pharmaceuticals. Recruiting at 65 sites in 19 countries. Open to participants aged 50 Years and older. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Geographic Atrophy by Novartis — 1 open to participants now, 1 under way, none of them phase 3. Geographic Atrophy · Novartis.
Among the 15 studies in Geographic Atrophy by Novartis, this one is the 5th largest by planned enrollment, is the only one that started in 2026, is one of 4 in phase 2, and was the 15th registered.
188 studies on the registry are indexed under Geographic Atrophy; 52 are open to participants now.
Browse Geographic Atrophy studies →1 of the 15 studies in Geographic Atrophy by Novartis is open now, in 12 countries.
By country, each count listing its studies:
Of the 40 Geographic Atrophy studies recruiting now, 31 (78%) set no upper age limit and none (0%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: 50 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 2010; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 272 is above the median of 70 across 141 interventional studies indexed under Geographic Atrophy.
Median enrollment 158 across the 15 interventional studies. Of the 14 that completed or were terminated, 11 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,720 studies on the registry; 221 are open to participants now.
Of its 586 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Geographic Atrophy by Novartis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To characterize the dose response relationship of FWY003 in participants with geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
This study is designed as a randomized, multi-center, double-masked, prospective study to characterize the dose response relationship, efficacy and safety of FWY003.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female participants ≥ 50 years of age.
A diagnosis of GA secondary to AMD in at least one eye (study eye). If both eyes qualify, then the eye with the better BCVA would be assigned as study eye.
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Participants will receive FWY003 dose level 1
Drug: FWY003
Participants will receive FWY003 dose level 2
Drug: FWY003
Participants will receive FWY003 dose level 3
Drug: FWY003
Participants will receive placebo
Drug: Placebo
FWY003 arm participants will receive a specific dose of FWY003
Placebo arm participants will receive placebo
Change of geographic atrophy (GA) lesion area in the study eye
To evaluate the dose response relationship of FWY003 on GA lesion area in the study eye in participants with GA secondary to age-related macular degeneration (AMD).
Time frame: From Baseline to Month 18
Number of participants with adverse events (AEs) and serious adverse events (SAEs)
To assess the safety and tolerability of FWY003.
Time frame: From first dose (Day 1) to Month 19
Change in visual function measure by ETDRS (Regular Luminance) Best Corrected Visual Acuity (BCVA) in the study eye
To assess the change in visual function over time by measuring Best Corrected Visual Acuity (BCVA) using the Early Treatment Diabetic Retinopathy Study (ETDRS) chart under normal lighting conditions. BCVA is the sharpest vision a person can achieve with optimal correction, such as glasses or contact lenses. The ETDRS eye chart is the standardized chart used in clinical trials.
Time frame: Baseline through Month 18
Change in visual function measure by ETDRS Low Luminance Visual Acuity (LLVA) in the study eye
To assess the change in visual function using Early Treatment Diabetic Retinopathy Study (ETDRS) Low Luminance Visual Acuity (LLVA) vision test. This test measures how well a person can see under low-light conditions. It is performed using the standard ETDRS eye chart.
Time frame: Baseline through Month 18
Change in visual function measure by Quantitative contrast sensitivity function (qCSF) under regular luminance in the study eye
To assess the change in visual function by using a test called the quantitative Contrast Sensitivity Function (qCSF). qCSF checks how faint a pattern a person can see, and how that changes for large vs. small details.
Time frame: Baseline through Month 18
Change in visual function measure by Low Contrast quantitative Visual Acuity (LCqVA) under regular luminance in the study eye
To assess the change in visual function using a test called Low Contrast quantitative Visual Acuity (LCqVA). LCqVA is visual acuity test where letters on the chart are printed with reduced contrast. The test is performed in normal lighting conditions.
Time frame: Baseline through Month 18
Change in visual function measure by LCqVA under low luminance in the study eye
To assess the change in visual function in dim-light conditions using a test called Low Contrast quantitative Visual Acuity (LCqVA). This test measures how well a person can read low-contrast letters. The test is performed with reduced luminance (making the environment darker).
Time frame: Baseline through Month 18
Proportion of participants with ≥15 letters loss
To measure how many participants in a study lose 15 or more letters on a visual test
Time frame: Baseline through Month 18
Change in area of total and partial ellipsoid zone (EZ) attenuation in the macula in the study eye
To assess the effect of FWY003 on photoreceptor parameters in the study eye.
Time frame: Baseline through Month 18
Plasma concentrations of FWY003
To assess the pharmacokinetic profile of FWY003.
Time frame: Baseline through Month 18
Rate of change of GA lesion area (square-root transformed) in the study eye
To assess the rate of change in GA lesion area in the study eye.
Time frame: Baseline through Month 18
Change of GA lesion area (square-root transformed)
To assess the effect of FWY003 on GA lesion area.
Time frame: Baseline through Month 12
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on www.clinicalstudydatarequest.com
No publications or documents are linked to this record.
Started Mar 2026 (actual). Primary completion is estimated for Aug 2029, 41 months after the start.
Of 24 phase 2 interventional studies under Geographic Atrophy, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 54. This study's planned 41 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.